|1.||Siegall, Clay B: 1 article (01/2005)|
|2.||Hellström, Ingegerd: 1 article (01/2005)|
|3.||Henry, Carolyn J: 1 article (01/2005)|
|4.||Hellström, Karl Erik: 1 article (01/2005)|
|5.||Buss, Michael S: 1 article (01/2005)|
|6.||Brewer, William G: 1 article (01/2005)|
|7.||Bryan, Jeffrey N: 1 article (01/2005)|
04/01/1993 - "When administered i.v. into athymic mice carrying L2987 tumor xenografts, BR96 sFv-PE40 was cleared rapidly from the blood with a half-life of approximately 30 min. This is in comparison to a chemical conjugate, chiBR96-LysPE40, that remained in the blood for almost 2 h. "
10/01/1995 - "BR96 sFv-PE40 was used to target established human tumor xenografts in both mice and in rats. "
03/01/1994 - "We conclude, therefore, that BR96 sFv-PE40 can cure tumor xenografts at well tolerated doses and also in the presence of Ley expression in normal tissues."
03/01/1994 - "H3396 tumor xenografts established in athymic mice (up to 350 mm3) and rats (up to 100 mm3) completely regressed after i.v. administration of BR96 sFv-PE40, given as 0.625 mg/kg (1.975 mg/m2) every 4th day for a total of five doses (mice) or 0.25 mg/kg (1.475 mg/m2) every 4th day for a total of four doses (rats). "
01/15/2005 - "Dogs with tumors expressing Le(y) antigen were offered enrollment in a clinical trial to receive twice-weekly infusions of 4 to 12 mg/m(2) BR96 sFv-PE40. "
10/01/1995 - "Complete regressions of lung, breast and bladder carcinomas were obtained in these models upon administration of well-tolerated doses of BR96 sFv-PE40. "
01/15/2005 - "Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma."
11/15/1997 - "To address this issue, we evaluated in preclinical models the concomitant use of the immunosuppressive agent CTLA4Ig and BR96 sFv-PE40, a single-chain immunotoxin that binds to carcinoma cells expressing Le(y). "
10/01/1995 - "While both forms of BR96 immunotoxin were equally cytotoxic to human carcinoma cell lines in vitro, the fusion protein form, BR96 sFv-PE40, was > 10-fold more active in vivo as an antitumor agent. "
03/01/1994 - "BR96 sFv-PE40 is a single-chain immunotoxin fusion protein targeted to the Ley Ag, which is expressed in many different human carcinomas as well as in normal gastrointestinal epithelium of humans and certain animals, including athymic rats but not mice. "
11/15/1997 - "Cotreatment with CTLA4Ig also prevented hypersensitivity reactions induced by repeat dosing of BR96 sFv-PE40 (q3dx5) in dogs. "
11/15/1997 - "It also blocked hypersensitivity reactions in rats carrying colon carcinoma allografts during a second course of BR96 sFv-PE40 therapy, and the cotreatment with CTLA4Ig resulted in enhanced antitumor activity. "
|4.||Breast Neoplasms (Breast Cancer)
|1.||Lewis Y antigen
|3.||Immunoglobulin G (IgG)
|6.||Recombinant DNA (Recombinant DNA Research)
|9.||monoclonal antibody BR96
|10.||recombinant HAR-TX beta 2 protein
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Homologous Transplantation (Allograft)